OptiBiotix Health PLC Director/PDMR Shareholding (3061K)
01 Settembre 2021 - 08:00AM
UK Regulatory
TIDMOPTI
RNS Number : 3061K
OptiBiotix Health PLC
01 September 2021
Opti B i otix Health plc
( "Opti Bi o t ix" or the "Company")
PDMR Dealing
Notification and public disclosure of a transaction by a person
discharging managerial responsibilities (PDMR).
OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness
d e vel o ping co m p o u n ds to tack le o besit y, high choleste
r ol, diabetes and skincare, announces that it received
notification on 31 August 2021 that René Kamminga (CEO, Optibiotix
Ltd), acquired 8,188 ordinary shares in the Company on 31 August
2021 at a price of 55.4 pence per share.
Following the transaction, Mr Kamminga is interested in 43,188
ordinary shares in the Company, representing 0.05% of the Company's
issued share capital.
This announcement contains inside information for the purposes
of the UK Market Abuse Regulation and the Directors of the Company
are responsible for the release of this announcement.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Neil Davidson, Chairman Contact via Walbrook
below
Stephen O'Hara, Chief Executive
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Cenkos Securities plc (Broker) Tel: 020 7397 8900
Callum Davidson / Neil McDonald
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D programme working with
leading academics in the development of microbial strains,
compounds, and formulations which are used as active ingredients
and supplements. More than twenty international food and healthcare
supplement companies have signed agreements with OptiBiotix to
incorporate their human microbiome modulators into a wide range of
food products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
------------------------------------------------------------------------------------------
a. Name René Kamminga
---------------------------------------- ------------------------------------------------
2 Reason for notification
---------------------------------------- ------------------------------------------------
a. Position/Status PDMR
---------------------------------------- ------------------------------------------------
b. Initial notification/ Initial Notification
Amendment
---------------------------------------- ------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------------------
a. Name OptiBiotix Health Plc
---------------------------------------- ------------------------------------------------
b. LEI 213800UKYQFT941QHS14
---------------------------------------- ------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
------------------------------------------------------------------------------------------
a. Description of 8,188 ordinary shares of 2p each
the financial
instrument, type
of instrument ISIN: GB00BP0RTP38
Identification
Code
---------------------------------------- ------------------------------------------------
b. Nature of the Purchase of 8,188 ordinary shares in the
transaction Company
---------------------------------------- ------------------------------------------------
c. Price(s) and volume(s) Price(s) per Volume(s)
share
---------------------------------------- -------------------------
55.4p 8,188
------------------------- ----------------
d. Aggregated information
* Volume n/a
* Price
---------------------------------------- ------------------------------------------------
e. Date of the transaction 31 August 2021
---------------------------------------- ------------------------------------------------
f. Place of the transaction London Stock Exchange, AIM
---------------------------------------- ------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHSDUEFFEFSESA
(END) Dow Jones Newswires
September 01, 2021 02:00 ET (06:00 GMT)
Grafico Azioni Optibiotix Health (LSE:OPTI)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Optibiotix Health (LSE:OPTI)
Storico
Da Mar 2023 a Mar 2024